Back to top

Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $31 and keeps a Buy rating on the shares. The firm views the...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Denali Therapeutics Inc. (DNLI)